Tags

Type your tag names separated by a space and hit enter

[Anabolic treatment for osteoporosis: PTH treatment].
Clin Calcium 2006; 16(9):1480-85CC

Abstract

There are several lines of evidence about the effectiveness of parathyroid hormone (PTH) as a bone anabolic reagent for the treatment of osteoporosis, and the large-scale randomized controlled trial revealed that PTH increases and reduces lumbar spine bone mineral density and fracture risk, respectively, more potently than other inhibitors for bone resorption. Moreover, alendronate was useful for the further increase in bone mineral density after the withdrawal of PTH treatment, and the combined treatment of PTH and raloxifene was additive. On the other hand, strontium ranelate significantly inhibited osteoporotic fractures in randomized placebo controlled trial, which is expected as a new bone anabolic reagent for osteoporosis.

Authors+Show Affiliations

Kobe University Graduate School of Medicine, Department of Clinical Molecular Medicine, Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

16951472

Citation

Kaji, Hiroshi, and Toshitsugu Sugimoto. "[Anabolic Treatment for Osteoporosis: PTH Treatment]." Clinical Calcium, vol. 16, no. 9, 2006, pp. 1480-85.
Kaji H, Sugimoto T. [Anabolic treatment for osteoporosis: PTH treatment]. Clin Calcium. 2006;16(9):1480-85.
Kaji, H., & Sugimoto, T. (2006). [Anabolic treatment for osteoporosis: PTH treatment]. Clinical Calcium, 16(9), pp. 1480-85.
Kaji H, Sugimoto T. [Anabolic Treatment for Osteoporosis: PTH Treatment]. Clin Calcium. 2006;16(9):1480-85. PubMed PMID: 16951472.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Anabolic treatment for osteoporosis: PTH treatment]. AU - Kaji,Hiroshi, AU - Sugimoto,Toshitsugu, PY - 2006/9/5/pubmed PY - 2007/1/11/medline PY - 2006/9/5/entrez SP - 1480 EP - 85 JF - Clinical calcium JO - Clin Calcium VL - 16 IS - 9 N2 - There are several lines of evidence about the effectiveness of parathyroid hormone (PTH) as a bone anabolic reagent for the treatment of osteoporosis, and the large-scale randomized controlled trial revealed that PTH increases and reduces lumbar spine bone mineral density and fracture risk, respectively, more potently than other inhibitors for bone resorption. Moreover, alendronate was useful for the further increase in bone mineral density after the withdrawal of PTH treatment, and the combined treatment of PTH and raloxifene was additive. On the other hand, strontium ranelate significantly inhibited osteoporotic fractures in randomized placebo controlled trial, which is expected as a new bone anabolic reagent for osteoporosis. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/16951472/[Anabolic_treatment_for_osteoporosis:_PTH_treatment]_ L2 - http://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -